Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Monoclonal antibodies (selective immunosuppressants). |
| Generic Name : | Infliximab - rheumatoid arthritis |
| Drug description : | Powder for concentrate for solution for infusion. |
| Presentation : | Powder, infliximab 100mg . |
| Indications : | Reduction of signs and symptoms of rheumatoid arthritis in patients with active disease when the response to disease-modifying drugs, including methotrexate, has been inadequate. Efficacy and safety have been demonstrated only in combination with methotrexate. Also indicated in Crohn's disease. |
| Adult Dosage : | 3mg/kg by intravenous infusion over two hours followed by additional 3mg/kg doses at two and six weeks after first infusion, then every eight weeks thereafter. Repeat if necessary 14 weeks after last infusion. Note: Remicade must be given concomitantly with methotrexate. |
| Child Dosage : | Children under 17 years, not recommended. recommended. |
| Contra Indications : | Sepsis or clinically manifest infections and/or abscesses. History of hypersensitivity to infliximab, to other murine proteins or to any of the excipients. Pregnancy or lactation within six months of dose (ensure adequate contraception). |
| Special Precautions : | Monitor closely for acute infusion reactions within two hours of dose; if necessary slow rate, interrupt infusion or discontinue. Ensure emergency treatment is available. Monitor for delayed hypersensitivity if patient retreated after prolonged period. Discontinue if lupus-like symptoms appear or if antinuclear antibodies are detected. Elderly, hepatic or renal impairment. |
| Adverse Reactions : | Viral infection, fever. Headache, vertigo, dizziness. Hypertension, flushing. UTIs. Upper and lower respiratory tract infection, dyspnoea, sinusitis. GI upset. Skin reactions. Fatigue, chest pain. |
| Manufacturer : | Schering-Plough |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org